Patents by Inventor Daqing Wang

Daqing Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 10066230
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 4, 2018
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 10041076
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 7, 2018
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20180044669
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: October 26, 2017
    Publication date: February 15, 2018
    Inventors: Sudhir AGRAWAL, Wayne JIANG, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20180023085
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: October 6, 2017
    Publication date: January 25, 2018
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • Compositions for inhibiting checkpoint gene expression and uses thereof
    Patent number: 9828601
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: November 28, 2017
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • WAVELENGTH BEAM COMBINING LASER SYSTEMS UTILIZING LENS ROLL FOR CHIEF RAY FOCUSING
    Publication number: 20170329147
    Abstract: In various embodiments, a wavelength beam combining laser system includes a fast-axis collimation lens that is rotated with respect to a plurality of emitters in order to converge the emitted beams onto a dispersive element and/or reduce the size of the multi-wavelength output beam of the system.
    Type: Application
    Filed: July 25, 2017
    Publication date: November 16, 2017
    Inventors: Michael Deutsch, Daqing Wang, James Zambuto, Bien Chann, Bryan Lochman
  • TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS
    Publication number: 20170274004
    Abstract: The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
    Type: Application
    Filed: June 6, 2017
    Publication date: September 28, 2017
    Inventors: Daqing Wang, Wayne Jiang, Sudhir Agrawal
  • TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF
    Publication number: 20170268006
    Abstract: The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 21, 2017
    Inventors: Sudhir Agrawal, Daqing Wang, Fu-Gang Zhu
  • Wavelength beam combining laser systems utilizing lens roll for chief ray focusing
    Patent number: 9746679
    Abstract: In various embodiments, a wavelength beam combining laser system includes a fast-axis collimation lens that is rotated with respect to a plurality of emitters in order to converge the emitted beams onto a dispersive element and/or reduce the size of the multi-wavelength output beam of the system.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: August 29, 2017
    Assignee: TERADIODE, INC.
    Inventors: Michael Deutsch, Daqing Wang, James Zambuto, Bien Chann, Bryan Lochman
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20170233741
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: December 1, 2016
    Publication date: August 17, 2017
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • OPTICAL ALIGNMENT SYSTEMS AND METHODS FOR WAVELENGTH BEAM COMBINING LASER SYSTEMS
    Publication number: 20170219835
    Abstract: In various embodiments, wavelength beam combining laser systems incorporate fast-axis collimation lenses and slow-axis collimation lenses (either separately or as portions of a single hybrid lens) optically upstream of an optical rotation system to thereby reduce or minimize cross-talk in the combined output beam.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: James Zambuto, Parviz Tayebati, Bien Chann, Michael Deutsch, Daqing Wang, Bryan Lochman
  • Toll-like receptor 9 antagonist and methods of use thereof
    Patent number: 9688993
    Abstract: The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: June 27, 2017
    Assignee: IDERA PHARMACEUTICALS, INC.
    Inventors: Sudhir Agrawal, Daqing Wang, Fu-Gang Zhu
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20170145417
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: August 16, 2016
    Publication date: May 25, 2017
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Optical alignment systems and methods for wavelength beam combining laser systems
    Patent number: 9658461
    Abstract: In various embodiments, wavelength beam combining laser systems incorporate fast-axis collimation lenses and slow-axis collimation lenses (either separately or as portions of a single hybrid lens) optically upstream of an optical rotation system to thereby reduce or minimize cross-talk in the combined output beam.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 23, 2017
    Assignee: TERADIODE, INC.
    Inventors: James Zambuto, Parviz Tayebati, Bien Chann, Michael Deutsch, Daqing Wang, Bryan Lochman
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9540651
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: January 10, 2017
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20160312225
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: July 13, 2016
    Publication date: October 27, 2016
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
    Patent number: 9453228
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: September 27, 2016
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF
    Publication number: 20160251652
    Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5?-ends to allow the presence of two or more accessible 3?-ends.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Inventors: Sudhir Agrawal, Wayne Jiang, Daqing Wang, Jessica Seitzer, Fu-Gang Zhu, Xianzhi Mao
  • TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF
    Publication number: 20160237437
    Abstract: The invention provides antagonist of TLR9 and methods of use thereof. These compounds inhibit or suppress TLR9-mediated signaling. The methods may have use in the prevention and treatment of diseases or disorders mediated by TLR9.
    Type: Application
    Filed: February 11, 2016
    Publication date: August 18, 2016
    Inventors: Sudhir Agrawal, Daqing Wang, Fu-Gang Zhu
  • IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
    Publication number: 20160215287
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: July 6, 2015
    Publication date: July 28, 2016
    Inventors: Ekambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal